IMMUNOHISTOCHEMICAL STUDY OF HER-2/neu AND E-CADHERIN IN colon CARCINOMA

CHF 99.60
Auf Lager
SKU
VBI9K5G4VO6
Stock 1 Verfügbar
Geliefert zwischen Fr., 19.09.2025 und Mo., 22.09.2025

Details

Colorectal cancer is one of the most common malignant diseases worldwide. Because the development of anti-tumor agents, therapeutic options have considerably improved. we Studied the expression of E-cadherin and Her- 2/neu in colon carcinoma trying to correlate between their expression and the prognosis of this disease.100 specimens of colorectal carcinomas were subjected to H&E staining and immunohistochemical staining for E-cadherin and Her2/neu. E-cadherin expression in colorectal carcinoma seemed to pass in chronological stages starting from its gradual absence from the membrane then its appearance in the cytoplasm and lastly its total loss. Also the over-expression of Her-2/neu protein and its positive relation with the poor prognostic variables may favor its role as prognostic marker in colorectal carcinoma and may become of great value in predicting the poor out come of the tumour. So both agents may act as prognostic markers to forecast the clinical course and outcome in colon cancer and as a predictive marker to predict the therapeutic response.

Autorentext

Dr. Hanan Alsaeid Alshenawy, lecturer of pathology (MD), Tanta University, Faculty of Medicine.

Cart 30 Tage Rückgaberecht
Cart Garantie

Weitere Informationen

  • Allgemeine Informationen
    • Sprache Englisch
    • Untertitel IMMUNOPATHOLOGY
    • Autor Hanan Alshenawy
    • Titel IMMUNOHISTOCHEMICAL STUDY OF HER-2/neu AND E-CADHERIN IN colon CARCINOMA
    • Veröffentlichung 22.02.2011
    • ISBN 3843394113
    • Format Kartonierter Einband
    • EAN 9783843394116
    • Jahr 2011
    • Größe H220mm x B150mm x T14mm
    • Gewicht 346g
    • Herausgeber LAP LAMBERT Academic Publishing
    • Anzahl Seiten 220
    • GTIN 09783843394116

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.